Diligence memo · auto-generated · as of July 3, 2026
GNT Pharmaceuticals, Inc.
GNT Pharmaceuticals, Inc. looks under-valued against its niche peers and is active on financing cadence.
Businessfiled
GNT Pharmaceuticals, Inc. operates in Pharmaceuticals, based in LOUISVILLE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
GNT Pharmaceuticals, Inc. has raised $150K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $150K on 2025-03-03.
Most recent recorded round closed around 2025-03-03.
Valuation (modeled)modeled
Provath models GNT Pharmaceuticals, Inc. at approximately $458K (range $84K–$1.3M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.31× the median modeled value of Pre-Seed Pharmaceuticals companies in 2025–2027 (19 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 16 mo ago; this sector typically re-raises about every 13 months.
Raising on or ahead of the sector's normal rhythm.
Comparablesmixed
Capital scale ranks ahead of 3% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 1% of those peers.
Closest niche peers: Fedora Pharmaceuticals Inc., PRG FlowChem, Inc., Adora Animal Health Corp, ABLi Therapeutics, Inc., NextEvo, Inc..
Peoplefiled
5 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.